Despite definitive mechanistic proof that a differential activation of the NLRP3 inflammasome due to altered PAMPs delivery to the hepatobiliary system during the course of cholestatic liver disease is missing, a number of studies have started to evaluate the role of NLRP3, especially in model systems, with interesting results. The gene discussed is NLRP3; the disease is Cholestatic liver disease.